The global gene amplification technology market size was valued at USD 10.13 billion in 2023 and is projected to reach USD 8.63 billion by 2030, growing at a CAGR of -0.5% from 2024 to 2030. Despite the slight negative growth rate, the market continues to be driven by the increasing demand for research and development in areas such as molecular diagnostics, genomics, biological research, and genetic testing. These applications are fueling the ongoing adoption of gene amplification technologies across academic, clinical, and industrial laboratories.

The market has also experienced a notable boost due to the development of multiple diagnostic tests for COVID-19, which leverage a variety of gene amplification techniques. The urgent global need for reliable and rapid testing has highlighted the importance of these technologies and accelerated their adoption in healthcare and research sectors.

A significant driver of market growth is the rapid advancement in DNA replication technologies. Innovative techniques such as loop-mediated amplification, along with alternatives like Nucleic Acid Sequence Based Amplification (NASBA), Rolling Circle Amplification (RCA), and Loop-Mediated Isothermal Amplification (LAMP), have undergone extensive research and development. These methods are increasingly preferred because they do not require costly thermal cyclers, offer rapid amplification rates, and can efficiently multiply genetic material from a single cell.

Key Market Trends & Insights:

• In 2023, North America dominated the global gene amplification technologies market, reflecting the region’s strong presence in research, diagnostics, and biotechnology innovation. The United States emerged as the leading contributor, accounting for a market share of 84.2% in 2023. This dominance can be attributed to the country’s well-established healthcare infrastructure, high investment in life sciences research, and early adoption of advanced gene amplification technologies.

• When analyzed by application, the diagnostics and pharmaceutical segment captured the largest revenue share, representing 72.7% of the market in 2023. This leadership is driven by the increasing demand for reliable molecular diagnostic tests, drug development, and personalized medicine solutions that rely heavily on gene amplification technologies.

• In terms of sample type, the cell lines segment held the largest revenue share, accounting for 39.8% in 2023. The widespread use of cell lines in research and diagnostic applications highlights their critical role in genetic testing, molecular biology experiments, and drug discovery processes.

• Based on end use, the Academic and Research Institutes segment captured the largest revenue share of 26.8% in 2023. The extensive use of gene amplification technologies in universities, research laboratories, and biotechnology centers underlines their importance in advancing scientific research, developing new diagnostic tools, and supporting innovations in genomics and molecular biology.

Order a free sample PDF of the Gene Amplification Technologies Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 10.13 Billion

• 2030 Projected Market Size: USD 8.63 Billion

• CAGR (2024-2030): -0.5%

• North America: Largest market in 2023

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some of the key companies operating in the global gene amplification technologies market include QIAGEN, New England Biolabs, Illumina, Inc., and others. These companies are actively employing various strategic initiatives, such as mergers and acquisitions, licensing agreements, and partnerships, to strengthen their market presence and expand their technological capabilities. In recent years, the market has witnessed a significant number of mergers and acquisitions, reflecting the competitive nature of the industry and the emphasis on consolidating technological expertise.

Illumina, Inc. is a leading provider in the genomics space, engaged in the creation, production, and sale of comprehensive systems for analyzing genetic variations and biological processes on a large scale. The company offers a wide range of products and services tailored to sequencing, genotyping, and gene expression applications, serving genomic research centers, pharmaceutical companies, academic institutions, and biotechnology firms. Illumina’s integrated solutions support advancements in genetic research and personalized medicine, making it a pivotal player in the gene amplification technologies market.

4basebio operates as an innovative biotechnology company focused on developing gene therapy technologies and solutions. The company specializes in researching and advancing nanoparticles for the delivery of nucleic acids without the use of viral vectors, representing a significant step forward in safe and effective gene therapy delivery systems. These innovations highlight the company’s commitment to advancing genetic research and expanding the practical applications of gene amplification technologies.

Key Players

• QIAGEN

• New England Biolabs

• Illumina Inc.

• Yikang Gene

• Bio-Rad Laboratories

• Silicon Biosystems

• Merck KGaA

• Promega Corporation

• Takara Bio Inc.

• Danaher Corporation

• 4basebio AG

• LGC Group

• Vazyme Biotech Co. Ltd.

• MyBioSource

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global gene amplification technologies market is experiencing a slight decline, primarily due to the stabilization of COVID-19-related diagnostic testing demand. However, the market continues to be driven by the increasing need for advanced research in molecular diagnostics, genomics, and genetic testing. Technological advancements in gene amplification methods, such as LAMP, NASBA, and RCA, are gaining popularity due to their cost-effectiveness and rapid amplification capabilities. These innovations are expected to sustain the utilization of gene amplification technologies in various applications, including diagnostics and pharmaceutical research.